Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019’, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH)

- The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Non-Alcoholic Steatohepatitis (NASH) therapeutics and enlists all their major and minor projects

- The report assesses Non-Alcoholic Steatohepatitis (NASH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

89bio Ltd

Abide Therapeutics Inc

AdAlta Ltd

Akcea Therapeutics Inc

Akero Therapeutics Inc

Albireo Pharma Inc

Aldeyra Therapeutics Inc

Allergan Plc

Allinky ...

3-V Biosciences Inc

89bio Ltd

Abide Therapeutics Inc

AdAlta Ltd

Akcea Therapeutics Inc

Akero Therapeutics Inc

Albireo Pharma Inc

Aldeyra Therapeutics Inc

Allergan Plc

Allinky Biopharma SL

Alteogen Inc

Angion Biomedica Corp

Araim Pharmaceuticals Inc

Arcturus Therapeutics Ltd

Ardelyx Inc

Ascletis Inc

Assembly Biosciences Inc

AstraZeneca Plc

Betagenon AB

BioElectron Technology Corp

Bird Rock Bio Inc

BLR Bio LLC

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Can-Fite BioPharma Ltd

Carmot Therapeutics Inc

Celgene Corp

Cerenis Therapeutics Holding SA

ChemoCentryx Inc

CJ HealthCare Corp

CohBar Inc

Coherus BioSciences Inc

ConSynance Therapeutics Inc

ContraVir Pharmaceuticals Inc

Corcept Therapeutics Inc

CymaBay Therapeutics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Dicerna Pharmaceuticals Inc

Dimerix Bioscience Pty Ltd

Dong-A Socio Holdings Co Ltd

DURECT Corp

Eli Lilly and Co

Enanta Pharmaceuticals Inc

Enyo Pharma SA

Esperion Therapeutics Inc

Exicure Inc

Forma Therapeutics Inc

Galectin Therapeutics Inc

Galecto Biotech AB

Galmed Pharmaceuticals Ltd

Gemphire Therapeutics Inc

Genfit SA

GenKyoTex SA

Gilead Sciences Inc

GRI Bio Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

Hana Pharm Co Ltd

Hanmi Pharmaceuticals Co Ltd

HemoShear Therapeutics, LLC

HotSpot Therapeutics Inc

IB Pharmaceuticals Inc

Immupharma Plc

Immuron Ltd

Indalo Therapeutics Inc

Integral Molecular Inc

Intercept Pharmaceuticals Inc

Inventiva

Inversago Pharma Inc

Ionis Pharmaceuticals Inc

Kowa Co Ltd

Kyorin Pharmaceutical Co Ltd

LG Chem Ltd

LifeMax Laboratories Inc

Lin Bioscience Inc

Lipocine Inc

Madrigal Pharmaceuticals Inc

MallInckrodt Plc

MedImmune LLC

Merck & Co Inc

Metabolys SAS

Metacrine Inc

Mina Therapeutics Ltd

Mitsubishi Tanabe Pharma Corp

Naia Ltd

Nash Pharmaceuticals Inc

NeuroVive Pharmaceutical AB

NGM Biopharmaceuticals Inc

Nippon Chemiphar Co Ltd

Novartis AG

Novo Nordisk AS

Nuevolution AB

NuSirt Biopharma Inc

Oramed Pharmaceuticals Inc

Pfizer Inc

Phanes Therapeutics Inc

Pharmaxis Ltd

Phenex Pharmaceuticals AG

Pliant Therapeutics Inc

Poxel SA

Promethera Biosciences SA

ProMetic Life Sciences Inc

Protalix BioTherapeutics Inc

Redx Pharma Plc

Regulus Therapeutics Inc

reMYND NV

Ritter Pharmaceuticals Inc

Saje Pharma LLC

Sancilio & Company Inc

Sanofi

ScandiCure AB

Second Genome Inc

Seres Therapeutics Inc

SFA Therapeutics LLC

Shenzhen HighTide Biopharmaceutical Ltd

Sihuan Pharmaceutical Holdings Group Ltd

Synlogic Inc

T3D Therapeutics Inc

TaiwanJ Pharmaceuticals Co Ltd

Terns Pharmaceuticals Inc

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

Vascular Biogenics Ltd

Verlyx Pharma Inc

Viking Therapeutics Inc

Visionary Pharmaceuticals Inc

Vivus Inc

WAVE Life Sciences Ltd

Yuhan Corp

Zafgen Inc

Zebra Discovery Ltd

Table of Contents

Table of Contents

Introduction

Non-Alcoholic Steatohepatitis (NASH) – Overview

Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Assessment

Non-Alcoholic Steatohepatitis (NASH) – ...

Table of Contents

Introduction

Non-Alcoholic Steatohepatitis (NASH) – Overview

Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Assessment

Non-Alcoholic Steatohepatitis (NASH) – Companies Involved in Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) – Drug Profiles

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects

Non-Alcoholic Steatohepatitis (NASH) – Discontinued Products

Non-Alcoholic Steatohepatitis (NASH) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by 3-V Biosciences Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by 89bio Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Abide Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by AdAlta Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Akcea Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Akero Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Albireo Pharma Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Aldeyra Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Allergan Plc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Allinky Biopharma SL, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Alteogen Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Angion Biomedica Corp, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Araim Pharmaceuticals Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Arcturus Therapeutics Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ardelyx Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ascletis Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Assembly Biosciences Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by AstraZeneca Plc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Betagenon AB, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by BioElectron Technology Corp, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Bird Rock Bio Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by BLR Bio LLC, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Boehringer Ingelheim GmbH, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Bristol-Myers Squibb Co, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Cadila Healthcare Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Can-Fite BioPharma Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Carmot Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Celgene Corp, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Cerenis Therapeutics Holding SA, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ChemoCentryx Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by CJ HealthCare Corp, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by CohBar Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Coherus BioSciences Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ConSynance Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ContraVir Pharmaceuticals Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Corcept Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by CymaBay Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Debiopharm International SA, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Dicerna Pharmaceuticals Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Dimerix Bioscience Pty Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by DURECT Corp, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Eli Lilly and Co, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Enanta Pharmaceuticals Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Enyo Pharma SA, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Esperion Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Exicure Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Forma Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Galectin Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Galecto Biotech AB, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Galmed Pharmaceuticals Ltd, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Gemphire Therapeutics Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Genfit SA, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by GenKyoTex SA, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Gilead Sciences Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by GRI Bio Inc, H1 2019

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2019

List of Figures

List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports